RT Journal Article
SR Electronic
T1 Geospatial analysis of malaria burden in Kagera region, North-western Tanzania using health facility and community survey data
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.06.11.24308780
DO 10.1101/2024.06.11.24308780
A1 Petro, Daniel A.
A1 Shaban, Nyimvua
A1 Aaron, Sijenunu
A1 Chacky, Frank
A1 Lazaro, Samwel
A1 Boni, Maciej F.
A1 Ishengoma, Deus S.
YR 2024
UL http://medrxiv.org/content/early/2024/06/23/2024.06.11.24308780.abstract
AB Generating evidence of malaria burden in areas with confirmed artemisinin partial resistance (ART-R) is the first step before developing a response strategy to the resistance. In this study, we assessed the burden of malaria in Kagera region (with recently confirmed ART-R) by geospatial analysis using data from health facilities (HFs) and community surveys from 2017 to 2023. In 2983717/8124363 patients from HFs, rapid diagnostic test positivity rate was 36.7% (range: 0-80%) and was similar in patients aged under-fives (33.1%, range: 0-79%) and ≥5 years (33.7%, range: 3-80%). The prevalence of malaria was 10.0% (range: 0-40.5%, n=84999/ 853761) in pregnant women but it was 26.1% (3409/13065) in school children (range: 0-78.4%). We identified hotspots and coldspots, and persistently high burden in 69/192 wards, school children, and patients aged ≥5 years, providing evidence for planning and developing an ART-R response for the region.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was partially funded by the National Institute for Medical Research (NIMR) under the MSMT project. The MSMT project is funded in whole, by the Bill & Melinda Gates Foundation [grant number INV 02202]. Under the grant conditions of the Foundation, a Creative Commons Attribution 4.0 Generic License has already been assigned to the author of the accepted Manuscript version that might arise from this submissionAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics committee/IRB of National Institute for Medical Research gave ethical approval for this work and permission to use the data was sought from the Permanent Secretary - Ministry of Health of Mainland TanzaniaI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesData used in this study are not publicly available and were obtained with a request from MoH through NMCP. Restrictions apply to the availability of this data and permission can be obtained with a reasonable request from the Permanent Secretary - Ministry of Health of Mainland Tanzania.